<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ren Fail</journal-id><journal-id journal-id-type="iso-abbrev">Ren Fail</journal-id><journal-id journal-id-type="pmc-domain-id">3421</journal-id><journal-id journal-id-type="pmc-domain">renfail</journal-id><journal-title-group><journal-title>Renal Failure</journal-title></journal-title-group><issn pub-type="ppub">0886-022X</issn><issn pub-type="epub">1525-6049</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11001372</article-id><article-id pub-id-type="pmcid-ver">PMC11001372.1</article-id><article-id pub-id-type="pmcaid">11001372</article-id><article-id pub-id-type="pmcaiid">11001372</article-id><article-id pub-id-type="pmid">38044852</article-id><article-id pub-id-type="doi">10.1080/0886022X.2023.2285873</article-id><article-id pub-id-type="publisher-id">2285873</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetic analysis of ceftazidime and cefazolin in the treatment of continuous ambulatory peritoneal dialysis-related peritonitis</article-title><alt-title alt-title-type="left-running-head">W. Zhu et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="W">Weiping</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AUFN1" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fang</surname><given-names initials="X">Xueling</given-names></name><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AUFN1" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="J">Jing</given-names></name><xref rid="AF0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ke</surname><given-names initials="Y">Ying</given-names></name><xref rid="AF0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="Q">Qiaolan</given-names></name><xref rid="AF0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cui</surname><given-names initials="T">Tongxia</given-names></name><xref rid="AF0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="B">Bairong</given-names></name><xref rid="AF0003" ref-type="aff">c</xref><xref rid="AN0002" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tian</surname><given-names initials="L">Lin</given-names></name><xref rid="AF0004" ref-type="aff">d</xref><xref rid="AN0001" ref-type="corresp"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Nephrology, The Fifth Affiliated Hospital of Sun Yat-Sen University</institution>, <city>Zhuhai</city>, <country>China</country></aff><aff id="AF0002"><label>b</label><institution>Department of Rheumatology, The Fifth Affiliated Hospital of Sun Yat-Sen University</institution>, <city>Zhuhai</city>, <country>China</country></aff><aff id="AF0003"><label>c</label><institution>Department of Cardiology, The Fifth Affiliated Hospital of Sun Yat-Sen University</institution>, <city>Zhuhai</city>, <country>China</country></aff><aff id="AF0004"><label>d</label><institution>Pharmaceutical Department, The Fifth Affiliated Hospital of Sun Yat-Sen University</institution>, <city>Zhuhai</city>, <country>China</country></aff></contrib-group><author-notes><fn id="AUFN1"><label>&#8224;</label><p>Weiping Zhu and Xueling Fang contributed equally to this study.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Lin Tian <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:tianlin@mail.sysu.edu.cn">tianlin@mail.sysu.edu.cn</email><institution>Pharmaceutical Department, the Fifth Affiliated Hospital of Sun Yat-Sen University</institution>, <addr-line>No. 52, Meihua Road, Xiangzhou District</addr-line><city>, Zhuhai</city>, <country>China</country></corresp><corresp id="AN0002">Bairong Chen <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:chenbr@mail.sysu.edu.cn">chenbr@mail.sysu.edu.cn</email><institution>Department of Cardiology, the Fifth Affiliated Hospital of Sun Yat-Sen University</institution>, <city>Zhuhai</city>, <country>China</country>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>4</day><month>12</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2023</year></pub-date><volume>45</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">445711</issue-id><elocation-id>2285873</elocation-id><pub-history><event event-type="pmc-release"><date><day>04</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>08</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-11 20:25:25.343"><day>11</day><month>04</month><year>2024</year></date></event><event event-type="received"><date><day>29</day><month>6</month><year>2023</year></date></event><event event-type="revised"><date><day>26</day><month>10</month><year>2023</year></date></event><event event-type="accepted"><date><day>15</day><month>11</month><year>2023</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>22</day><month>3</month><year>2024</year></date></event><event event-type="final"><event-desc>published online as a final version in an issue</event-desc><date><day>22</day><month>3</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="IRNF_45_2285873.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="IRNF_45_2285873.pdf"/><abstract><title>Abstract</title><sec><title>Objective</title><p>Peritoneal dialysis-related peritonitis (PDRP) presents a significant challenge for nephrologists. Continuous intraperitoneal cefazolin and ceftazidime are recommended for the treatment of peritonitis. However, some pharmacokinetic studies have shown that doses of 15&#8211;20&#8201;mg/kg/d may not achieve sufficient therapeutic levels. In this study, we investigated the pharmacokinetics of ceftazidime and cefazolin in patients with continuous ambulatory peritoneal dialysis-related peritonitis and compared the pharmacokinetic characteristics between traditional and modified treatment groups.</p></sec><sec><title>Methods</title><p>From February 2017 to December 2019, 42 PDRP patients (17 males, 25 females; mean age: 50.7&#8201;&#177;&#8201;12.1&#8201;years; mean body weight: 60.9&#8201;&#177;&#8201;11.8&#8201;kg) were recruited for the study, all participants were anuric. Twenty patients were enrolled in the traditional group and treated with cefazolin (1.0&#8201;g) and ceftazidime (1.0&#8201;g) <italic toggle="yes">via</italic> intraperitoneal administration once daily for 14&#8201;days. Twenty-two patients were enrolled in the modified group and received the same dose of antibiotics twice daily for the initial five days, followed by once daily for the subsequent nine days. Serum and dialysate samples were collected after days 1, 2, 3, 5, 7, 10, and 14 and analyzed <italic toggle="yes">via</italic> liquid chromatography-mass spectrometry.</p></sec><sec><title>Results</title><p>In the traditional group, the highest and lowest serum concentrations of ceftazidime were 35.9 and 21.7&#8201;&#181;g/mL, respectively. The highest concentration of cefazolin was 54.6&#8201;&#181;g/mL on day 5 and the lowest concentration was 30.4&#8201;&#181;g/mL on day 1. In the modified group, the highest and lowest serum concentrations of ceftazidime were 102.2 and 54.8&#8201;&#181;g/mL, respectively. The highest concentration of cefazolin was 141.7&#8201;&#181;g/mL and the lowest concentration was 79.8&#8201;&#181;g/mL. All antibiotic concentrations were above the minimum inhibitory concentration (MIC) level (8&#8201;&#181;g/mL of ceftazidime and 2&#8201;&#181;g/mL of cefazolin) throughout the treatment period. However, on day 1, the concentration of ceftazidime in the third bag of dialysate effluent from the traditional group fell below the MIC level. Despite remaining above the MIC, cefazolin concentration was consistently lower in the third bag of dialysate effluent from the traditional group throughout the treatment period.</p></sec><sec><title>Conclusions</title><p>Intraperitoneal administration of cefazolin and ceftazidime at a dose of 1&#8201;g twice daily for 5&#8201;days and then once daily for the rest of the treatment period ensured adequate therapeutic levels of antibiotics for treating anuric PDRP patients.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Pharmacokinetics</kwd><kwd>peritonitis</kwd><kwd>ceftazidime</kwd><kwd>cefazolin</kwd></kwd-group><support-group><funding-group><funding-statement>This study was not supported by any source and represents an original effort by us.</funding-statement></funding-group></support-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="7"/><word-count count="4096"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="S0001"><label>1.</label><title>Introduction</title><p>Peritoneal-dialysis associated peritonitis (PDRP) is a common complication of peritoneal dialysis and serves as the primary reason for patients transitioning to hemodialysis. Guidelines from the International Society for Peritoneal Dialysis (ISPD) published in 2016, recommend that timely and adequate use of antibiotics is the most important part of treatment. Empirical treatment should be initiated as soon as possible after obtaining microbiological specimens, comprised of a first-generation cephalosporin or vancomycin for Gram-positive organisms and a third-generation cephalosporin or an aminoglycoside for Gram-negative organisms [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Intraperitoneal administration of antibiotics ensures that concentrations at local sites of infection are maximized, but absorption into the systemic circulation is also possible, potentially leading to toxicity. If this is accompanied by deterioration of renal function, clearance of ceftazidime <italic toggle="yes">via</italic> the biliary route becomes more significant [<xref rid="CIT0002" ref-type="bibr">2</xref>]. Considering that peritoneal membrane function in peritonitis patients may differ from that in healthy individuals, application of pharmacokinetic/pharmacodynamic principles of antibiotic therapy can lead to dosing recommendations that optimize antibiotic efficacy and minimize toxicity [<xref rid="CIT0003" ref-type="bibr">3</xref>, <xref rid="CIT0004" ref-type="bibr">4</xref>]. According to the ISPD 2016 recommendations, once-daily intraperitoneal cefazolin at a dose of 15&#8211;20&#8201;mg/kg/d and ceftazidime at a dose of 1&#8211;1.5&#8201;g daily is recommended. However, some pharmacokinetic studies have shown that these doses may not provide adequate therapeutic levels throughout the treatment period [<xref rid="CIT0005" ref-type="bibr">5</xref>, <xref rid="CIT0006" ref-type="bibr">6</xref>]. To date, comprehensive pharmacokinetic data are limited for cefazolin and ceftazidime over the whole treatment period in PDRP. The recommended dosages of many antibiotics for the treatment of PDRP are based on published clinical experience rather than formal pharmacokinetic studies [<xref rid="CIT0007" ref-type="bibr">7</xref>]. The aim of this study was therefore to determine whether adequate levels of cefazolin and ceftazidime in dialysate and serum could be achieved with two different dosing approaches. In the traditional group, intraperitoneal administration was performed once daily for 14&#8201;days. In the modified group, patients were dosed twice daily for 5&#8201;days and then once daily for the following 9&#8201;days.</p></sec><sec sec-type="materials" disp-level="1" id="S0002"><label>2.</label><title>Materials and methods</title><sec disp-level="2" id="S0002-S2001"><label>2.1.</label><title>Patients</title><p>This trial recruited patients diagnosed with PDRP based on ISPD recommendations, who had been on continuous ambulatory peritoneal dialysis for no less than four weeks, and were anuric. All participants provided informed consent. Patients who were allergic to cephalosporin antibiotics or were pregnant were excluded. Infections with MRSA, ESBL or other cephalosporin-resistant strains were excluded from our study. <italic toggle="yes">Mycobacterium tuberculosis</italic> or fungal infection cases were also excluded. Enterococcus infections would be treated with vancomycin or other sensitive antibiotics when the culture results were obtained and the data would not be collected for the study. Each patient received four daily dialysate exchanges, with a volume of 2&#8201;L per exchange, using 1.5% or 2.5% low calcium dialysate. Approval was obtained from the Ethics Committee of the Fifth Affiliated Hospital of Sun Yat-Sen University, and the study was registered on ClinicalTrials.gov (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04367974">NCT04367974</ext-link>).</p></sec><sec disp-level="2" id="S0002-S2002"><label>2.2.</label><title>Drugs and administration</title><p>Cefazolin (Xin Tai Lin, Gosun, Shenzhen, China) and ceftazidime (Fortum, GSK, Brentford, UK) were co-administered at a dosage of 1&#8201;g/d by intraperitoneal administration, as an intermittent prescription of antibiotic. In the traditional group, intraperitoneal administration was performed once daily in the fourth bag (first bag (DS1): 08:00&#8211;12:00; second bag (DS2): 12:00&#8211;16:00; third bag (DS3): 16:00&#8211;20:00; fourth bag (DS4): 20:00&#8211;08:00) for 14&#8201;days. In the modified group, intraperitoneal administration was performed twice daily (1&#8201;g/dose &#215; 2 doses) in the first and fourth bags for 5&#8201;days and then once daily (1&#8201;g/dose &#215; 1 dose) in the fourth bag on the following 9&#8201;days. The first admixed bag was infused into the peritoneal cavity and allowed to dwell for 4&#8201;h and the fourth admixed bag was allowed to dwell throughout the night. Every patient in both groups received treatment with cefazolin and ceftazidime throughout the therapy period. The physical characteristics and white blood cell (WBC) count of the dialysis solution were monitored every day. If the dialysis solution was completely clear within three days and the WBC count decreased to normal levels, the treatment duration was 14&#8201;days. Conversely, if the dialysis solution did not clear entirely in three days and the WBC count remained elevated, the treatment extended to 21&#8201;days.</p></sec><sec disp-level="2" id="S0002-S2003"><label>2.3.</label><title>Sample collection</title><p>Samples of serum (&#8805; 1&#8201;mL) and dialysate (&#8805; 5&#8201;mL) were collected at 1, 2, 3, 5, 7, 10, and 14&#8201;days after complete instillation of the dialysis containing antibiotics into the peritoneal cavity. The serum samples were collected at 6 am. For patients treated with antibiotics twice (the modified group), samples were collected at the following times: DS4-08:00, DS1-12:00, DS2-16:00, DS3-20:00. DS4 and DS1 contained antibiotics. DS4 was retained in the abdominal cavity throughout the night from 20:00 the day before until 08:00, at which time the samples were collected. DS1 was retained in the abdominal cavity for 4&#8201;h before sample collection at 12:00. DS2 and DS3, which did not contain antibiotics, were retained in the abdominal cavity for 4&#8201;h. Serum samples were collected at 06:00, coinciding with the lowest level. For patients who were treated with antibiotics once (the traditional group), samples were collected at the following times: DS4-08:00, DS1-12:00, DS2-16:00, DS3-20:00. Only DS4 contained antibiotics. DS4 was retained in the abdominal cavity throughout the night from 20:00 the day before until 08:00, at which time the samples were collected. All collected samples were centrifuged at 1500&#215;<italic toggle="yes">g</italic> and frozen at &#8722;80&#8201;&#176;C within 1&#8201;h of collection.</p></sec><sec disp-level="2" id="S0002-S2004"><label>2.4.</label><title>Bacterial culture</title><p>The samples were collected in resin-containing BACTEC PLUS blood culture bottles and cultured using a BACTEC 9120 automatic culture meter (BD Company, NJ, USA). If the culture results were positive, the bacteria were transferred onto a chocolate agar plate to complete bacterial identification using a PHOENIX 100 analyzer (BD Company).</p></sec><sec disp-level="2" id="S0002-S2005"><label>2.5.</label><title>Concentration determination</title><p>Cefazolin and ceftazidime concentrations were determined by liquid chromatography-mass spectrometry (LC-MS). A ZORBAX C18 chromatography column (ZORBAX SB-C18 50&#8201;&#215;&#8201;2.1&#8201;mm, 1.8&#8201;&#181;m, Agilent, USA) was used. The mobile phase was composed of A (0.1% formic acid) and B (0.1% formic acid in acetonitrile) at a flow rate of 0.3&#8201;mL/min. Detection was completed using an electrospray ion source operating in positive ion mode and implementing multiple reaction monitoring. The precision of the procedure was under 15%, with accuracy ranging from 85 to 115%. The lower limits of quantification for cefazolin and ceftazidime were 0.05&#8211;1.0&#8201;&#181;g/mL.</p></sec><sec disp-level="2" id="S0002-S2006"><label>2.6.</label><title>Statistical analysis</title><p>All data were analyzed using SPSS (version 18, SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5 (GraphPad Software, USA). The data are presented as the mean&#8201;&#177;&#8201;standard deviation (SD). A threshold of <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 indicated a statistically significant difference.</p></sec></sec><sec sec-type="results" disp-level="1" id="S0003"><label>3.</label><title>Results</title><sec disp-level="2" id="S0003-S2001"><label>3.1.</label><title>Study subjects</title><p>From February 2017 to December 2019, 22 patients (nine males, 13 females; mean age: 51.4&#8201;&#177;&#8201;15.6&#8201;years; mean body weight: 60.7&#8201;&#177;&#8201;10.3&#8201;kg) with peritonitis were recruited into the modified group and 20 patients (eight males, 12 females; mean age: 49.8&#8201;&#177;&#8201;8.7&#8201;years; mean body weight: 61.5&#8201;&#177;&#8201;13.7&#8201;kg) were recruited into the traditional group for the study. The average duration of peritoneal dialysis in the traditional group was 38.3&#8201;&#177;&#8201;28.9&#8201;months and in the modified group was 39.2&#8201;&#177;&#8201;25.4&#8201;months. All participants in the study were anuric. Primary diseases included diabetes, chronic glomerulonephritis, gouty nephropathy, hypertension, and obstructive nephropathy. No significant difference was observed in the baseline data between the two groups. The laboratory blood and dialysate data are shown in <xref rid="t0001" ref-type="table">Table 1</xref>. The culture results showed that eighteen cases (81.8%) were positive for bacteria, including eleven (50.0%) Gram-positive strains and seven (31.8%) Gram-negative strains in the modified group. Sixteen cases (80.0%) were positive for bacteria in the traditional group, including nine (45.0%) Gram-positive strains and seven (35.0%) Gram-negative strains (<xref rid="t0002" ref-type="table">Table 2</xref>). The basic clinical data did not show a significant difference between the traditional and modified groups. In terms of efficacy, 80% (16/20) of patients in the traditional group were discharged after improvement, while four patients failed to recover in 14&#8201;days and eventually one patient had to be switched to hemodialysis, and 100% (22/22) of patients were cured in the modified group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.043).</p><table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Continuous ambulatory peritoneal dialysis patient clinical data.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th rowspan="2" align="left" colspan="1">Clinical variables</th><th align="center" colspan="1" rowspan="1">Modifed group</th><th align="center" colspan="1" rowspan="1">Traditional group</th></tr><tr><th align="center" colspan="1" rowspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;22)</th><th align="center" colspan="1" rowspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;20)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">Age(years)</td><td align="char" char="." colspan="1" rowspan="1">51.4&#8201;&#177;&#8201;15.6</td><td align="char" char="." colspan="1" rowspan="1">49.8&#8201;&#177;&#8201;8.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Body weight(kg)</td><td align="char" char="." colspan="1" rowspan="1">60.7&#8201;&#177;&#8201;10.3</td><td align="char" char="." colspan="1" rowspan="1">61.5&#8201;&#177;&#8201;13.7</td></tr><tr><td align="left" colspan="1" rowspan="1">WBC in Blood (&#215; 10<sup>9</sup>/L)</td><td align="char" char="." colspan="1" rowspan="1">9.2&#8201;&#177;&#8201;4.3</td><td align="char" char="." colspan="1" rowspan="1">8.7&#8201;&#177;&#8201;4.1</td></tr><tr><td align="left" colspan="1" rowspan="1">Hemoglobin (g/L)</td><td align="char" char="." colspan="1" rowspan="1">98.7&#8201;&#177;&#8201;17.7</td><td align="char" char="." colspan="1" rowspan="1">101.0&#8201;&#177;&#8201;12.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Platelets (&#215; 10<sup>9</sup>/L)</td><td align="char" char="." colspan="1" rowspan="1">272.5&#8201;&#177;&#8201;116.0</td><td align="char" char="." colspan="1" rowspan="1">255.1&#8201;&#177;&#8201;98.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Procalcitonin (&#181;g/L)</td><td align="char" char="." colspan="1" rowspan="1">5.9&#8201;&#177;&#8201;12.6</td><td align="char" char="." colspan="1" rowspan="1">6.4&#8201;&#177;&#8201;7.9</td></tr><tr><td align="left" colspan="1" rowspan="1">hsCRP (mg/L)</td><td align="char" char="." colspan="1" rowspan="1">69.8&#8201;&#177;&#8201;69.1</td><td align="char" char="." colspan="1" rowspan="1">65.4&#8201;&#177;&#8201;55.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Serum potassium (mmol/L)</td><td align="char" char="." colspan="1" rowspan="1">3.4&#8201;&#177;&#8201;0.7</td><td align="char" char="." colspan="1" rowspan="1">3.5&#8201;&#177;&#8201;0.8</td></tr><tr><td align="left" colspan="1" rowspan="1">Serum phosphorus (mmol/L)</td><td align="char" char="." colspan="1" rowspan="1">1.4&#8201;&#177;&#8201;0.6</td><td align="char" char="." colspan="1" rowspan="1">1.6&#8201;&#177;&#8201;0.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Serum calcium (mmol/L)</td><td align="char" char="." colspan="1" rowspan="1">2.1&#8201;&#177;&#8201;0.2</td><td align="char" char="." colspan="1" rowspan="1">2.0&#8201;&#177;&#8201;0.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Serum creatinine (mg/dL)</td><td align="char" char="." colspan="1" rowspan="1">9.2&#8201;&#177;&#8201;2.2</td><td align="char" char="." colspan="1" rowspan="1">9.5&#8201;&#177;&#8201;1.8</td></tr><tr><td align="left" colspan="1" rowspan="1">Percentage of polynuclear cells</td><td align="char" char="." colspan="1" rowspan="1">73.6&#8201;&#177;&#8201;26.8</td><td align="char" char="." colspan="1" rowspan="1">69.8&#8201;&#177;&#8201;23.4</td></tr><tr><td align="left" colspan="1" rowspan="1">in dialysate</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">WBC in dialysate (&#215; 10<sup>6</sup>/L)</td><td align="char" char="." colspan="1" rowspan="1">1321.5&#8201;&#177;&#8201;1168.0</td><td align="char" char="." colspan="1" rowspan="1">1273.6&#8201;&#177;&#8201;986.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Serum albumin (g/L)</td><td align="char" char="." colspan="1" rowspan="1">31.9&#8201;&#177;&#8201;5.7</td><td align="char" char="." colspan="1" rowspan="1">30.3&#8201;&#177;&#8201;6.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Length of hospitalization(days)</td><td align="char" char="." colspan="1" rowspan="1">15.6&#8201;&#177;&#8201;4.8</td><td align="char" char="." colspan="1" rowspan="1">16.7&#8201;&#177;&#8201;5.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Duration of pain(days)</td><td align="char" char="." colspan="1" rowspan="1">6.6&#8201;&#177;&#8201;5.5</td><td align="char" char="." colspan="1" rowspan="1">6.9&#8201;&#177;&#8201;5.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Cure rate</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Gram positive</td><td align="char" char="." colspan="1" rowspan="1">11/11</td><td align="char" char="." colspan="1" rowspan="1">7/9</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Gram negative</td><td align="char" char="." colspan="1" rowspan="1">7/7</td><td align="char" char="." colspan="1" rowspan="1">5/7</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Culture negative</td><td align="char" char="." colspan="1" rowspan="1">4/4</td><td align="char" char="." colspan="1" rowspan="1">4/4</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Total</td><td align="char" char="." colspan="1" rowspan="1">22/22*</td><td align="char" char="." colspan="1" rowspan="1">16/20</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>The clinical data of all patients were collected and are shown as means&#8201;&#177;&#8201;SD, *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, ** <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01. There was no difference between the traditional and modified groups.</p></fn><fn id="TF2"><p>WBC, white blood cell; hsCRP, high sensitivity C-creative protein.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>Bacterial culture results.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th rowspan="2" align="left" colspan="1">Pathogenic bacteria</th><th align="center" colspan="1" rowspan="1">Modifed group</th><th align="center" colspan="1" rowspan="1">Traditional group</th></tr><tr><th align="center" colspan="1" rowspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;22)</th><th align="center" colspan="1" rowspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;20)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Staphylococcus</italic>
</td><td align="char" char="." colspan="1" rowspan="1">6</td><td align="char" char="." colspan="1" rowspan="1">5</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;<italic toggle="yes">Staph. aureus</italic></td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;<italic toggle="yes">Staphy. saprophyticus</italic></td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;<italic toggle="yes">Staphy. haemolyticus</italic></td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;<italic toggle="yes">Staphy. Epidermidis</italic></td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;<italic toggle="yes">Staphy. warneri</italic></td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Streptococcus viridans</italic>
</td><td align="char" char="." colspan="1" rowspan="1">5</td><td align="char" char="." colspan="1" rowspan="1">4</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Escherichia coli</italic>
</td><td align="char" char="." colspan="1" rowspan="1">3</td><td align="char" char="." colspan="1" rowspan="1">4</td></tr><tr><td align="left" colspan="1" rowspan="1">Others</td><td align="char" char="." colspan="1" rowspan="1">4</td><td align="char" char="." colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;<italic toggle="yes">Enterobacter cloacae</italic></td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;<italic toggle="yes">Klebsiella pneumoniae</italic></td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;<italic toggle="yes">Acinetobacter baumannii</italic></td><td align="char" char="." colspan="1" rowspan="1">1</td><td align="char" char="." colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Culture negative</italic>
</td><td align="char" char="." colspan="1" rowspan="1">4</td><td align="char" char="." colspan="1" rowspan="1">4</td></tr></tbody></table><table-wrap-foot><fn id="TF3"><p>Dialysate samples were collected from every patient and cultured. The pathogenic bacteria are shown. If the result was negative after one week of culture, it is shown as &#8216;culture negative&#8217;. The other pathogenic bacteria included <italic toggle="yes">Listeria monocytogenes</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Stenotrophomonas maltophilia</italic>, anaerobic bacteroides and proteus.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="2" id="S0003-S2002"><label>3.2.</label><title>Drug metabolism and pharmacokinetics</title><sec disp-level="3" id="S0003-S2002-S3001"><label>3.2.1.</label><title>Serum</title><p>In the traditional group, the highest concentrations of ceftazidime and cefazolin were 35.9 and 54.6&#8201;&#181;g/mL on day 14, respectively (<xref rid="F0001" ref-type="fig">Figure 1</xref>). The corresponding lowest concentrations were 21.7 and 30.4&#8201;&#181;g/mL on day 1. In the modified group, the highest concentrations of ceftazidime and cefazolin reached 102.2 and 141.7&#8201;&#181;g/mL on day 14, respectively. The lowest concentration of ceftazidime was 54.8&#8201;&#181;g/mL and that of cefazolin was 79.8&#8201;&#181;g/mL on day 1. All recorded concentrations surpassed the Clinical and Laboratory Standards Institute&#8217;s (CLSI) recommended minimum inhibitory concentration (MIC) level (8&#8201;&#181;g/mL for ceftazidime and 2&#8201;&#181;g/mL for cefazolin). The half-lives of ceftazidime and cefazolin were 15.8 and 36.5&#8201;h, respectively (<xref rid="t0003" ref-type="table">Table 3</xref>). The mean concentration of cefazolin was significantly higher than that of ceftazidime (<italic toggle="yes">p</italic>&#8201;=&#8201;0.02).</p><fig position="float" id="F0001" orientation="portrait"><label>Figure 1.</label><caption><p>Concentration-time profiles of cefazolin and ceftazidime. Drug concentration-time profiles in plasma or the first bag of dialysate effluent (DS4), which was kept in the abdominal cavity throughout the night, on days 1, 2, 3, 5, 7, 10, and 14 after intraperitoneal administration of ceftazidime and cefazolin. The dotted line is minimum inhibitory concentration (MIC), which is recommended as 8 &#181;g/mL. Data are shown as means&#8201;&#177;&#8201;SD.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" position="float" orientation="portrait" xlink:href="IRNF_A_2285873_F0001_B.jpg"/></fig><table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3.</label><caption><p>Pharmacokinetic parameters.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Parameters</th><th align="center" colspan="1" rowspan="1">Ceftazidime</th><th align="center" colspan="1" rowspan="1">Cefazolin</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">t</italic><sub>1/2</sub> (h)</td><td align="char" char="." colspan="1" rowspan="1">15.8&#8201;&#177;&#8201;1.0</td><td align="char" char="." colspan="1" rowspan="1">36.5&#8201;&#177;&#8201;3.9</td></tr><tr><td align="left" colspan="1" rowspan="1">AUC (&#181;g&#8201;&#215;&#8201;d/mL)</td><td align="char" char="." colspan="1" rowspan="1">902.0&#8201;&#177;&#8201;2.1</td><td align="char" char="." colspan="1" rowspan="1">1380.0&#8201;&#177;&#8201;22.2</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">F</italic>
</td><td align="char" char="." colspan="1" rowspan="1">88.9% &#177; 1.9</td><td align="char" char="." colspan="1" rowspan="1">94.9% &#177; 0.8</td></tr><tr><td align="left" colspan="1" rowspan="1">CL (L/d)</td><td align="char" char="." colspan="1" rowspan="1">1.0&#8201;&#177;&#8201;0.1</td><td align="char" char="." colspan="1" rowspan="1">0.7&#8201;&#177;&#8201;0.1</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub>d</sub> (L)</td><td align="char" char="." colspan="1" rowspan="1">21.7&#8201;&#177;&#8201;1.3</td><td align="char" char="." colspan="1" rowspan="1">36.8&#8201;&#177;&#8201;15.2</td></tr></tbody></table><table-wrap-foot><fn id="TF4"><p>The <italic toggle="yes">t</italic><sub>1/2</sub> (plasma elimination half-life) was calculated by: <italic toggle="yes">t</italic><sub>1/2</sub> = 0.693/<italic toggle="yes">k</italic>, where <italic toggle="yes">k</italic> was determined from the negative slope of the log-transformed plasma concentration-time data over 5&#8211;14&#8201;days. AUC is the area under the plasma concentration-time curve from 0 to infinity. <italic toggle="yes">F</italic> is the bioavailability of the drug, calculated by: <italic toggle="yes">F</italic> = (dose added to dialysate &#8211; amount in effluent)/dose added to dialysate. CL is the total clearance: CL = (<italic toggle="yes">F</italic> &#215; Dose)/AUC. <italic toggle="yes">V</italic><sub>d</sub> is the volume of distribution. When <italic toggle="yes">V</italic><sub>d</sub> is large, the drug is more widely distributed in the body: <italic toggle="yes">V</italic><sub>d</sub> = CL/<italic toggle="yes">k</italic>.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="3" id="S0003-S2002-S3002"><label>3.2.2.</label><title>Dialysate</title><p>The highest and lowest concentrations of ceftazidime in the traditional group were 47.7&#8201;&#181;g/mL on day 14 and 30.4&#8201;&#181;g/mL on day 1 in DS4, respectively (<xref rid="F0002" ref-type="fig">Figure 2</xref>). The highest concentration of cefazolin was 39.0&#8201;&#181;g/mL and the lowest concentration was 20.3&#8201;&#181;g/mL in DS4. In the modified group, the highest and lowest concentrations of ceftazidime were 211.6 and 55.4&#8201;&#181;g/mL in DS4, respectively. The highest concentration of cefazolin was 134.2&#8201;&#181;g/mL and the lowest concentration was 25.6&#8201;&#181;g/mL in DS4. In both groups, the concentrations of ceftazidime and cefazolin in DS4 were higher than the MIC level every day. The <italic toggle="yes">T</italic><sub>max</sub> of both drugs was on the fifth day. In the modified group, the concentrations of both drugs were above the MIC level in every bag of dialysate. However, the ceftazidime concentration in the third bag of dialysate effluent in the traditional group was below the MIC level on day 1. The cefazolin concentrations were all above the MIC but were at a lower level in the third bag of dialysate effluent in the traditional group throughout the treatment period.</p><fig position="float" id="F0002" orientation="portrait"><label>Figure 2.</label><caption><p>Dialysate concentration-time profiles of the antibiotics. The concentration-time profiles of cefazolin and ceftazidime in peritoneal effluent on days 1, 2, 3, 5, 7, 10, and 14 after complete instillation into the peritoneal cavity for 4&#8201;h. The dotted line is minimum inhibitory concentration (MIC), which is recommended as 8 &#181;g/mL. DS1: the second bag of dialysate effluent. DS2: the third bag of dialysate effluent. DS3: the fourth bag of dialysate effluent. Data are shown as means&#8201;&#177;&#8201;SD.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" position="float" orientation="portrait" xlink:href="IRNF_A_2285873_F0002_C.jpg"/></fig></sec><sec disp-level="3" id="S0003-S2002-S3003"><label>3.2.3.</label><title>Pharmacokinetic parameters</title><p>A non-compartmental approach was used to analyze the data. The data showed that the half-life, area under the concentration-time curve (AUC) and apparent volume of distribution (Vd) of cefazolin were higher than those of ceftazidime (<xref rid="t0003" ref-type="table">Table 3</xref>).</p></sec></sec></sec><sec sec-type="discussion" disp-level="1" id="S0004"><label>4.</label><title>Discussion</title><p>Ceftazidime and cefazolin are both time-dependent antibiotics. Cefazolin lacks post-antibiotic effects, and when the concentration is less than the MIC, its antibacterial activity may be weakened. Consequently, the time of the concentration remains above MIC (T&#8201;&gt;&#8201;MIC) and AUC/MIC (AUIC) are often used to evaluate the curative effect. Greater clinical cure rates and bacteriological eradication are observed when T&#8201;&gt;&#8201;MIC is 100% or AUIC &#8805; 250 [<xref rid="CIT0008" ref-type="bibr">8</xref>]. However, Cardone et&#160;al. [<xref rid="CIT0009" ref-type="bibr">9</xref>] analyzed the ceftazidime dosing recommendations in PDRP patients and found that daily intraperitoneal dosing (1.0&#8201;g) may not provide adequate dialysate exposure on day 1. For peritonitis, a 3.0&#8201;g loading dose with maintenance dosing of 1.0&#8211;2.0&#8201;g daily or 2.0&#8201;g every 2&#8201;days was recommended. Booranalertpaisarn et&#160;al. [<xref rid="CIT0010" ref-type="bibr">10</xref>] also discovered that a dosing regimen of ceftazidime comprising a loading dose of 500&#8201;mg/L in dialysate and a continuous maintenance dose of 125&#8201;mg/L in dialysate did not provide sufficient dialysate levels of ceftazidime throughout 24&#8201;h. These studies indicated that 20&#8201;mg/kg/d of ceftazidime might not be sufficient and pharmacokinetic study is necessary to ensure a good clinical outcome. Some studies have shown that a daily dose of 1.0&#8201;g might be sufficient, but residual renal function in some patients might affect drug metabolism. Furthermore, the <italic toggle="yes">C</italic><sub>min</sub> values observed in some studies were very close to 8&#8201;&#181;g/mL and if the study was short-term, there might not have been sufficient time to observe longer-term changes of antibiotic concentrations [<xref rid="CIT0011" ref-type="bibr">11</xref>, <xref rid="CIT0012" ref-type="bibr">12</xref>].</p><p>In this study, we also considered the potential variation in pharmacokinetic parameters during an episode of peritonitis. Intraperitoneal administration of drugs may result in greater absorption and higher plasma concentrations. Furthermore, the clearance rates of creatinine and protein may change during peritonitis and the elimination of drugs may also change [<xref rid="CIT0013" ref-type="bibr">13</xref>, <xref rid="CIT0014" ref-type="bibr">14</xref>].</p><p>Furthermore, the prolongation of half-life and decreased excretion of drugs could potentially lead to side effects and toxicity. The most common side effect of cephalosporins is allergic reaction, but they can also cause bone marrow suppression, hepatic dysfunction, gastrointestinal dysfunction and neurotoxicity. Neurotoxicity is a serious potential side effect of cephalosporins and can include cataplexy, myoclonus, seizures, twitching, and disorientation. High doses, long treatment time, central nervous system disorders, and renal failure appear to be common precipitating factors [<xref rid="CIT0015" ref-type="bibr">15</xref>]. To prevent neurotoxicity, the maximum recommended plasma concentration of ceftazidime is 128&#8201;&#181;g/mL [<xref rid="CIT0016" ref-type="bibr">16</xref>] and that of cefazolin is 200&#8201;&#181;g/mL according to previous reports [<xref rid="CIT0017" ref-type="bibr">17</xref>, <xref rid="CIT0018" ref-type="bibr">18</xref>]. In our study, the highest plasma concentration of ceftazidime was 102.2&#8201;&#181;g/mL and that of cefazolin was 141.7&#8201;&#181;g/mL, below the recommended maximum. There were no severe adverse reactions observed during treatment.</p><p>For cefazolin and ceftazidime, the drug concentrations exceeding MIC are more important in determining efficacy than the magnitude of the highest concentration above MIC [<xref rid="CIT0019" ref-type="bibr">19</xref>, <xref rid="CIT0020" ref-type="bibr">20</xref>]. In our study, intraperitoneal administration of cefazolin (1.0&#8201;g) and ceftazidime (1.0&#8201;g) was performed twice daily in the first and fourth bags for 5&#8201;days and then once daily in the fourth bag on the following days. As shown in <xref rid="F0001" ref-type="fig">Figures 1</xref> and <xref rid="F0002" ref-type="fig">2</xref>, intraperitoneal administration resulted in a high initial plasma concentration. The mean serum and dialysate concentrations were above the upper limit of susceptibility for cephalosporins and T&#8201;&gt;&#8201;MIC was 100%. The mean half-lives of ceftazidime and cefazolin were significantly prolonged (15.8 and 36.5&#8201;h, respectively) compared to those in healthy individuals (1.5&#8211;2&#8201;h). Steady-state would be achieved after 5 half-lives, which is about 182.5&#8201;h for cefazolin. This explained why the serum concentrations of cefazolin were always higher than those of ceftazidime after intraperitoneal administration of the same doses of cefazolin and ceftazidime. Furthermore, the concentrations of ceftazidime and cefazolin were above the MIC in all of the peritoneal effluent samples and we also discovered that on the fifth day of treatment, the maximum plasma concentrations of cefazolin and ceftazidime reached highest levels, and all plasma concentrations were above the MIC. The results indicated that intraperitoneal administration ensured that antibiotic concentrations in the abdominal cavity were adequate.</p><p>In conclusion, the intraperitoneal administration of cefazolin at a dosage of 15&#8211;20&#8201;mg/kg/d and ceftazidime at a dosage of 1&#8211;1.5&#8201;g may prove insufficient for patients with no residual. Our therapeutic regimen was effective, safe, and could be used for treating PDRP. Considering that some PDRP patients might have preserved renal function, further study is needed to explore a precise dosage according to renal function such that the co-administration of ceftazidime and cefazolin could be adjusted to individualize the dose.</p></sec></body><back><ack><title>Acknowledgements</title><p>We are grateful for the hard work of the peritoneal dialysis team of our peritoneal dialysis center.</p></ack><sec sec-type="COI-statement" disp-level="1" id="S0005"><title>Disclosure statement</title><p>The authors declare that there are no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></sec><sec disp-level="1" id="S0006"><title>Ethical approval</title><p>The study protocol was approved by the Ethics Committee of the Fifth Affiliated Hospital of Sun Yat-Sen University.</p></sec><sec disp-level="1" id="S0007"><title>Informed consent to participate</title><p>All patients provided informed consent to participate in the study after the protocols and associated risks were explained to them individually.</p></sec><sec disp-level="1" id="S0008"><title>Trial registration</title><p>The study was registered on ClinicalTrials.gov (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04367974">NCT04367974</ext-link>).</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>PK-T</given-names></string-name>, <string-name name-style="western"><surname>Szeto</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Piraino</surname><given-names>B</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>ISPD peritonitis recommendations: 2016 update on prevention and treatment</article-title>. <source>Perit Dial Int</source>. <year>2016</year>;<volume>36</volume>(<issue>5</issue>):<fpage>1</fpage>&#8211;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.3747/pdi.2016.00078</pub-id>.<pub-id pub-id-type="pmcid">PMC5033625</pub-id><pub-id pub-id-type="pmid">27282851</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grabe</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Bailie</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Eisele</surname><given-names>G</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Pharmacokinetics of intermittent intraperitoneal ceftazidime</article-title>. <source>Am J Kidney Dis</source>. <year>1999</year>;<volume>33</volume>(<issue>1</issue>):<fpage>111</fpage>&#8211;<lpage>117</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0272-6386(99)70265-9</pub-id>.<pub-id pub-id-type="pmid">9915275</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Manley</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Bailie</surname><given-names>GR.</given-names></string-name></person-group><article-title>Treatment of peritonitis in APD: pharmacokinetic principles</article-title>. <source>Semin Dial</source>. <year>2002</year>;<volume>15</volume>(<issue>6</issue>):<fpage>418</fpage>&#8211;<lpage>421</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1525-139x.2002.00103.x</pub-id>.<pub-id pub-id-type="pmid">12437537</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ranganathan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Fassett</surname><given-names>RG</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study</article-title>. <source>BMC Nephrol</source>. <year>2009</year>;<volume>10</volume>(<issue>1</issue>):<fpage>42</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2369-10-42</pub-id>.<pub-id pub-id-type="pmid">20003546</pub-id><pub-id pub-id-type="pmcid">PMC2800106</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>T</surname><given-names>G.</given-names></string-name></person-group><article-title>Intermittent versus continuous antibiotics for Pd -Related peritonitis</article-title>. <source>Perit Dial Int</source>. <year>1997</year>;<volume>17</volume>(<issue>1</issue>):<fpage>11</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">9068015</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tosukhowong</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Eiam&#8211;Ong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Thamutok</surname><given-names>K</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients</article-title>. <source>Perit Dial Int</source>. <year>2001</year>;<volume>21</volume>(<issue>6</issue>):<fpage>587</fpage>&#8211;<lpage>594</lpage>. doi: <pub-id pub-id-type="doi">10.1177/089686080102100609</pub-id>.<pub-id pub-id-type="pmid">11783768</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>PK-T</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>Y</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment</article-title>. <source>Perit Dial Int</source>. <year>2022</year>;<volume>42</volume>(<issue>2</issue>):<fpage>110</fpage>&#8211;<lpage>153</lpage>. doi: <pub-id pub-id-type="doi">10.1177/08968608221080586</pub-id>.<pub-id pub-id-type="pmid">35264029</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKinnon</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Paladino</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Schentag</surname><given-names>JJ.</given-names></string-name></person-group><article-title>Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T&#8201;&gt;&#8201;MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections</article-title>. <source>Int J Antimicrob Agents</source>. <year>2008</year>;<volume>31</volume>(<issue>4</issue>):<fpage>345</fpage>&#8211;<lpage>351</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2007.12.009</pub-id>.<pub-id pub-id-type="pmid">18313273</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cardone</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Grabe</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Zasowski</surname><given-names>EJ</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>(<issue>1</issue>):<fpage>19</fpage>&#8211;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00873-13</pub-id>.<pub-id pub-id-type="pmid">24126585</pub-id><pub-id pub-id-type="pmcid">PMC3910753</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Booranalertpaisarn</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Eiam-Ong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wittayalertpanya</surname><given-names>S</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Pharmacokinetics of ceftazidime in CAPD-related peritonitis</article-title>. <source>Perit Dial Int</source>. <year>2003</year>;<volume>23</volume>(<issue>6</issue>):<fpage>574</fpage>&#8211;<lpage>579</lpage>. doi: <pub-id pub-id-type="doi">10.1177/089686080302300610</pub-id>.<pub-id pub-id-type="pmid">14703199</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elwell</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Manley</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Frye</surname><given-names>RF</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients</article-title>. <source>Int J Artif Organs</source>. <year>2005</year>;<volume>28</volume>(<issue>8</issue>):<fpage>808</fpage>&#8211;<lpage>816</lpage>. doi: <pub-id pub-id-type="doi">10.1177/039139880502800807</pub-id>.<pub-id pub-id-type="pmid">16211531</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Demotes-Mainard</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Vin&#231;on</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ragnaud</surname><given-names>JM</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis</article-title>. <source>J Clin Pharmacol</source>. <year>1993</year>;<volume>33</volume>(<issue>5</issue>):<fpage>475</fpage>&#8211;<lpage>479</lpage>. doi: <pub-id pub-id-type="doi">10.1002/j.1552-4604.1993.tb04691.x</pub-id>.<pub-id pub-id-type="pmid">8331207</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Manley</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Bailie</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Frye</surname><given-names>R</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis</article-title>. <source>J Am Soc Nephrol</source>. <year>2000</year>;<volume>11</volume>(<issue>7</issue>):<fpage>1310</fpage>&#8211;<lpage>1316</lpage>. doi: <pub-id pub-id-type="doi">10.1681/ASN.V1171310</pub-id>.<pub-id pub-id-type="pmid">10864588</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Monta&#241;&#233;s Pauls</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Almi&#241;ana</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Casab&#243; Al&#243;s</surname><given-names>VG.</given-names></string-name></person-group><article-title>Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis</article-title>. <source>Eur J Pharm Sci</source>. <year>2011</year>;<volume>43</volume>(<issue>4</issue>):<fpage>212</fpage>&#8211;<lpage>216</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejps.2011.04.006</pub-id>.<pub-id pub-id-type="pmid">21540106</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Al-Sadawi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez Ortega</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>N</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Jerky movement with ceftazidime: a case of ceftazidime-Induced neurotoxicity with a review of the literature</article-title>. <source>Case Rep Med</source>. <year>2019</year>. 2019;<volume>2019</volume>:<fpage>8936478</fpage>.<pub-id pub-id-type="pmid">31915439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2019/8936478</pub-id><pub-id pub-id-type="pmcid">PMC6930738</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moriyama</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Henning</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Neuhauser</surname><given-names>MM</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria</article-title>. <source>Ann Pharmacother</source>. <year>2009</year>;<volume>43</volume>(<issue>7</issue>):<fpage>1324</fpage>&#8211;<lpage>1337</lpage>. doi: <pub-id pub-id-type="doi">10.1345/aph.1L638</pub-id>.<pub-id pub-id-type="pmid">19584386</pub-id><pub-id pub-id-type="pmcid">PMC10807507</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ortiz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Martin-Llonch</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Garr&#243;n</surname><given-names>MP</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Cefazolin-induced encephalopathy in uremic patients</article-title>. <source>Rev Infect Dis</source>. <year>1991</year>;<volume>13</volume>(<issue>4</issue>):<fpage>772</fpage>&#8211;<lpage>773</lpage>. doi: <pub-id pub-id-type="doi">10.1093/clinids/13.4.772</pub-id>.<pub-id pub-id-type="pmid">1925303</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moore</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Bechtel</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Ayers</surname><given-names>LW.</given-names></string-name></person-group><article-title>Effect of multidose therapy on cerebrospinal fluid penetration of cefazolin</article-title>. <source>Am J Hosp Pharm</source>. <year>1981</year>;<volume>38</volume>(<issue>10</issue>):<fpage>1496</fpage>&#8211;<lpage>1499</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ajhp/38.10.1496</pub-id>.<pub-id pub-id-type="pmid">7294044</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blum</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cunha</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Cunha</surname><given-names>BA.</given-names></string-name></person-group><article-title>Lack of pharmacokinetic basis of weight-based dosing and intra-operative re-dosing with cefazolin surgical prophylaxis in obese patients: implications for antibiotic stewardship</article-title>. <source>Surg Infect (Larchmt)</source>. <year>2019</year>;<volume>20</volume>(<issue>6</issue>):<fpage>439</fpage>&#8211;<lpage>443</lpage>. doi: <pub-id pub-id-type="doi">10.1089/sur.2019.039</pub-id>.<pub-id pub-id-type="pmid">31112072</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kwee</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname><given-names>SAN</given-names></string-name>, <string-name name-style="western"><surname>Elligsen</surname><given-names>M</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Outcomes in documented Pseudomonas aeruginosa bacteremia treated with intermittent IV infusion of ceftazidime, meropenem, or Piperacillin-Tazobactam: a retrospective study</article-title>. <source>Can J Hosp Pharm</source>. <year>2015</year>;<volume>68</volume>(<issue>5</issue>):<fpage>386</fpage>&#8211;<lpage>394</lpage>. doi: <pub-id pub-id-type="doi">10.4212/cjhp.v68i5.1485</pub-id>.<pub-id pub-id-type="pmid">26478584</pub-id><pub-id pub-id-type="pmcid">PMC4605462</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>